The Indian Consensus Document on cardiac biomarker
I Satyamurthy1, Jamshed J Dalal2, J P S Sawhney3
1Director, Cardiology, Department of Cardiology at Apollo Hospitals, Chennai, India.
Insights
Diagnosing and managing heart failure remains challenging. Biomarkers offer valuable insights into heart failure (HF) severity and prognosis, potentially improving clinical assessments and patient outcomes.
Area of Science:
- Cardiology
- Biochemistry
Background:
- Heart failure (HF) diagnosis and management present ongoing clinical challenges.
- Common causes of congestive heart failure (CHF) in India include coronary artery disease, diabetes mellitus, and hypertension.
- Recent advancements in understanding CHF pathophysiology have led to the evolution of biomarkers.
Framework:
- Biomarkers in CHF reflect the extent of pathophysiological derangement.
- Examples include markers of myocyte necrosis, myocardial remodeling, and neurohormonal activation.
- Biomarkers indicate the presence, severity, and prognosis of CHF.
Implementation:
- Biomarkers can be used alongside conventional clinical assessments.
- They provide a feasible alternative to current expensive diagnostic measurements.
- Integration of biomarkers may offer significant clinical benefits in HF management.
Implications:
- Biomarkers enhance the diagnostic and prognostic capabilities in heart failure.
- They offer a cost-effective approach to assessing disease severity.
- Improved biomarker utilization can lead to better clinical decision-making and patient care.
Abstract:
Despite recent advances, the diagnosis and management of heart failure evades the clinicians. The etiology of congestive heart failure (CHF) in the Indian scenario comprises of coronary artery disease, diabetes mellitus and hypertension. With better insights into the pathophysiology of CHF, biomarkers have evolved rapidly and received diagnostic and prognostic value. In CHF biomarkers prove as measures of the extent of pathophysiological derangement; examples include biomarkers of myocyte necrosis, myocardial remodeling, neurohormonal activation, etc. In CHF biomarkers act as indicators for the presence, degree of severity and prognosis of the disease, they may be employed in combination with the present conventional clinical assessments. These make the biomarkers feasible options against the present expensive measurements and may provide clinical benefits.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
10:01Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies
Cardiovascular Drugs: Classification based on Therapeutic Indications
Imaging Studies for Cardiovascular System IV: CMRI
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
